SynthesisPsychological medicine2017
Predicting relapse after antidepressant withdrawal - a systematic review.
Synthesis in Psychological medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 3 syntheses or guidelines pooled it, 99 citations in OpenAlex.
- Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults: Réseau canadien pour les traitements de l'humeur et de l'anxiété (CANMAT) 2023 : Mise à jour des lignes directrices cliniques pour la prise en charge du trouble dépressif majeur chez les adultes.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2024Guideline
- Risk factors for relapse and recurrence of depression in adults and how they operate: A four-phase systematic review and meta-synthesis.Clinical psychology review · 2018Pooled it
- Diving and antidepressants.Diving and hyperbaric medicine · 2017Guideline
- Amygdala Reactivity, Antidepressant Discontinuation, and Relapse.JAMA psychiatry · 2024Trial
- Computational Mechanisms of Effort and Reward Decisions in Patients With Depression and Their Association With Relapse After Antidepressant Discontinuation.JAMA psychiatry · 2020Trial
- Relapse prevention with levomilnacipran ER in adults with major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled study.Depression and anxiety · 2019Trial
- Article
- Delay discounting correlates with depression but does not predict relapse after antidepressant discontinuation.Molecular psychiatry · 2026Article
- to extrapolation of primary absorbed compounds as multifunctional proxies of Zhiqiao ()-Houpo () herb pair.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2026Article
- Flavonoids and miRNA Modulation: A Novel Approach to Managing Cancer, Diabetes, Depression, and Neurological Disorders.BioMed research international · 2026Review
- Inflammatory and MRI perfusion biomarkers in predicting persistence of depression: a 6-month Longitudinal Study.Translational psychiatry · 2025Article
- Clinical Implications of Antidepressants and Associated Risk of Bleeding: A Narrative Review.Current pain and headache reports · 2025Review
- Perspectives on the ketogenic diet as a non-pharmacological intervention for major depressive disorder.Trends in psychiatry and psychotherapy · 2025Review
- The role of empathy in antidepressant withdrawal.Therapeutic advances in psychopharmacology · 2025Article
- Major depression symptom severity associations with willingness to exert effort and patch foraging strategy.medRxiv : the preprint server for health sciences · 2024Article
- Discontinuation of psychotropic medication: a synthesis of evidence across medication classes.Molecular psychiatry · 2024Review
- Microbiota-derived tryptophan metabolism and AMPK/mTOR pathway mediate antidepressant-like effect of Shugan Hewei Decoction.Frontiers in pharmacology · 2024Article
- In-person psychoeducational intervention to reduce rehospitalizations and improve the clinical course of major depressive disorder: a non-randomized pilot study.Frontiers in psychiatry · 2024Article
- Identifying relapse predictors in individual participant data with decision trees.BMC psychiatry · 2023Article
- Real-time monitoring of increases in restlessness to assess idiographic risk of recurrence of depressive symptoms.Psychological medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A substantial proportion of the burden of depression arises from its recurrent nature. The risk of relapse after antidepressant medication (ADM) discontinuation is high but not uniform. Predictors of individual relapse risk after antidepressant discontinuation could help to guide treatment and mitigate the long-term course of depression. We conducted a systematic literature search in PubMed to identify relapse predictors using the search terms '(depress* OR MDD*) AND (relapse* OR recurren*) AND (predict* OR risk) AND (discontinu* OR withdraw* OR maintenance OR maintain or continu*) AND (antidepress* OR medication OR drug)' for published studies until November 2014. Studies investigating predictors of relapse in patients aged between 18 and 65 years with a main diagnosis of major depressive disorder (MDD), who remitted from a depressive episode while treated with ADM and were followed up for at least 6 months to assess relapse after part of the sample discontinued their ADM, were included in the review. Although relevant information is present in many studies, only 13 studies based on nine separate samples investigated predictors for relapse after ADM discontinuation. There are multiple promising predictors, including markers of true treatment response and the number of prior episodes. However, the existing evidence is weak and there are no established, validated markers of individual relapse risk after antidepressant cessation. There is little evidence to guide discontinuation decisions in an individualized manner beyond overall recurrence risk. Thus, there is a pressing need to investigate neurobiological markers of individual relapse risk, focusing on treatment discontinuation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.